RVVTF (Revive Therapeutics) Debt-to-Equity : 0.00 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Revive Therapeutics Debt-to-Equity?

Revive Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Revive Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Revive Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $4.99 Mil. Revive Therapeutics's debt to equity for the quarter that ended in Sep. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Revive Therapeutics's Debt-to-Equity or its related term are showing as below:

During the past 11 years, the highest Debt-to-Equity Ratio of Revive Therapeutics was 0.93. The lowest was 0.00. And the median was 0.02.

RVVTF's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Revive Therapeutics Debt-to-Equity Historical Data

The historical data trend for Revive Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Debt-to-Equity Chart

Revive Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.01

0.03

0.02

Revive Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.01	-	-

Competitive Comparison of Revive Therapeutics's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revive Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's Debt-to-Equity falls into.

Revive Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Revive Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.018	+	0)	/	5.277
	=	0.00

Revive Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	4.99
	=	0.00

Revive Therapeutics (OTCPK:RVVTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Revive Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Revive Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (OTCPK:RVVTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

31R:Germany RVV:Canada

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1

Website

https://www.revivethera.com

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.